Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
23.37
+0.61 (2.68%)
At close: May 9, 2025, 4:00 PM
22.99
-0.38 (-1.63%)
After-hours: May 9, 2025, 7:40 PM EDT
Catalyst Pharmaceuticals Revenue
Catalyst Pharmaceuticals had revenue of $141.42M in the quarter ending March 31, 2025, with 43.56% growth. This brings the company's revenue in the last twelve months to $534.65M, up 29.97% year-over-year. In the year 2024, Catalyst Pharmaceuticals had annual revenue of $491.73M with 23.49% growth.
Revenue (ttm)
$534.65M
Revenue Growth
+29.97%
P/S Ratio
5.09
Revenue / Employee
$2,953,845
Employees
181
Market Cap
2.85B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 491.73M | 93.53M | 23.49% |
Dec 31, 2023 | 398.20M | 184.00M | 85.90% |
Dec 31, 2022 | 214.20M | 73.37M | 52.10% |
Dec 31, 2021 | 140.83M | 21.76M | 18.27% |
Dec 31, 2020 | 119.07M | 16.77M | 16.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CPRX News
- 1 day ago - Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 9 days ago - Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025 - GlobeNewsWire
- 17 days ago - Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewsWire
- 4 weeks ago - Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals - GlobeNewsWire
- 6 weeks ago - Strong Revenue, Drug Performance Lift Catalyst Shares - FXEmpire
- 2 months ago - Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts - Seeking Alpha
- 2 months ago - Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference - GlobeNewsWire